Results 31 to 40 of about 141,477 (341)

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Atorvastatin and Clopidogrel [PDF]

Circulation, 2003
To the Editor: I would like to comment on the recent editorial by Serebruany et al1 in which the study results by Lau et al2 are discussed. It is argued that these results, which are suggestive of a clinically relevant interaction between clopidogrel and atorvastatin, are in conflict with those published previously by Serebruany et al.3 According to ...
openaire   +3 more sources

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?

European Journal of Medical Research, 2010
Background Dual therapy with aspirin and clopidogrel increases the risk of gastrointestinal bleeding. Therefore, co-therapy with a proton pump inhibitor (PPI) is recommended by most guidelines.
Kenngott S, Olze R, Kollmer M, Bottheim H, Laner A, Holinski-Feder E, Gross M   +6 more
doaj   +1 more source

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2019
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option.
Hirotoshi Watanabe, T. Domei, T. Morimoto, M. Natsuaki, H. Shiomi, T. Toyota, M. Ohya, S. Suwa, K. Takagi, M. Nanasato, Yoshiki Hata, Masahiro Yagi, N. Suematsu, Takafumi Yokomatsu, I. Takamisawa, M. Doi, T. Noda, H. Okayama, Yoshitane Seino, T. Tada, H. Sakamoto, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, K. Hanaoka, Y. Morino, K. Kozuma, K. Kadota, Y. Furukawa, Y. Nakagawa, Takeshi Kimura   +34 more
semanticscholar   +1 more source

Adherence to secondary stroke prevention strategies - Results from the German stroke data bank [PDF]

, 2003
Only very limited data are available concerning patient adherence to antithrombotic medication intended to prevent a recurrent stroke. Reduced adherence and compliance could significantly influence the effects of any stroke prevention strategies.
Busse, O., Diener, H. C., Glahn, J., Hamann, Gerhard F., Weimar, C.   +4 more
core   +1 more source

Clopidogrel and Aspirin in Acute Ischemic Stroke and High‐Risk TIA

New England Journal of Medicine, 2018
BACKGROUND Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA).
S. Johnston, D. Easton, M. Farrant, W. Barsan, R. Conwit, C. Johnston, J. Easton, J. Elm, A. Kim, Anne S. Lindbald, Y. Palesch   +10 more
semanticscholar   +1 more source

A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI

Indian Heart Journal, 2015
Background: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival.
P.C. Rath, Sundar Chidambaram, Pallavi Rath, Byomakesh Dikshit, Sudhir Naik, Prashant K. Sahoo, Brajraj Das, Mohanshankar Mahalingam, Lakshmipathi Khandrika, Jugnu Jain   +9 more
doaj   +1 more source

Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset [PDF]

, 2010
<p><b>Background and Purpose:</b> Antiplatelets (APs) may increase the risk of symptomatic intracerebral hemorrhage (ICH) following intravenous thrombolysis after ischemic stroke.</p> <p><b>Methods:</b> We ...
Ahmed, N., Diedler, J., Ford, G.A., Lees, K.R., Luijckx, G.J., Overgaard, K., Ringleb, P., Soinne, L., Sykora, M., Uyttenboogaart, M., Wahlgren, N.   +10 more
core   +2 more sources

Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Journal of the American Medical Association (JAMA), 2020
Importance Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial.
S. You, Yeunsook Rho, B. Bikdeli, Jiwoo Kim, Anastasios Siapos, J. Weaver, A. Londhe, Jaehyeong Cho, Jimyung Park, M. Schuemie, M. Suchard, D. Madigan, G. Hripcsak, Aakriti Gupta, C. Reich, P. Ryan, R. W. Park, H. Krumholz   +17 more
semanticscholar   +1 more source